Rilonacept Granted FDA Priority Review

Regeneron Pharmaceuticals announced that the FDA has granted priority review status to the biologics license application for rilonacept for the long-term treatment of cryopyrin-associated periodic syndromes (CAPS). 

The FDA is expected to take action on the rilonacept application by the end of November, Regeneron said. 

Currently, there are no medicines approved for patients suffering from CAPS, a spectrum of rare inherited inflammatory conditions, including familial cold autoinflammatory syndrome and Muckle-Wells Syndrome, the company added.